CN117402851A - Polyglucose kinase mutant and application thereof - Google Patents
Polyglucose kinase mutant and application thereof Download PDFInfo
- Publication number
- CN117402851A CN117402851A CN202311176882.2A CN202311176882A CN117402851A CN 117402851 A CN117402851 A CN 117402851A CN 202311176882 A CN202311176882 A CN 202311176882A CN 117402851 A CN117402851 A CN 117402851A
- Authority
- CN
- China
- Prior art keywords
- mutant
- kinase
- polyglucose
- formula
- arabinose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract description 40
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract description 40
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 16
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 15
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 claims abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000002777 nucleoside Substances 0.000 claims description 11
- 108010042149 Polyphosphate-glucose phosphotransferase Proteins 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 8
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- GBXZONVFWYCRPT-JGWLITMVSA-N [(2r,3s,4r,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] dihydrogen phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)OP(O)(O)=O GBXZONVFWYCRPT-JGWLITMVSA-N 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 238000006276 transfer reaction Methods 0.000 claims description 2
- 150000008209 arabinosides Chemical class 0.000 abstract description 13
- -1 2-amino ara-adenosine Chemical compound 0.000 abstract description 11
- 230000035772 mutation Effects 0.000 abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract description 7
- 229960000684 cytarabine Drugs 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 239000000758 substrate Substances 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 abstract 2
- 229960003636 vidarabine Drugs 0.000 abstract 2
- NYHBQMYGNKIUIF-FJFJXFQQSA-N 9-beta-D-arabinofuranosylguanine Chemical compound C12=NC(N)=NC(O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O NYHBQMYGNKIUIF-FJFJXFQQSA-N 0.000 abstract 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 41
- 102000004190 Enzymes Human genes 0.000 description 40
- 230000003197 catalytic effect Effects 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 229920000388 Polyphosphate Polymers 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 239000001205 polyphosphate Substances 0.000 description 8
- 235000011176 polyphosphates Nutrition 0.000 description 8
- 108010021582 Glucokinase Proteins 0.000 description 7
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 7
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 102000030595 Glucokinase Human genes 0.000 description 6
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 6
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 241001235254 Thermococcus kodakarensis Species 0.000 description 5
- 239000002215 arabinonucleoside Substances 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 229940127073 nucleoside analogue Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000831564 Chloracidobacterium thermophilum Species 0.000 description 3
- 102000006405 Uridine phosphorylase Human genes 0.000 description 3
- 108010019092 Uridine phosphorylase Proteins 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100036286 Purine nucleoside phosphorylase Human genes 0.000 description 2
- 102000001853 Pyrimidine Phosphorylases Human genes 0.000 description 2
- 108010054917 Pyrimidine Phosphorylases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010009099 nucleoside phosphorylase Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000567139 Aeropyrum pernix Species 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000186073 Arthrobacter sp. Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000611898 Geobacillus stearothermophilus Pyrimidine-nucleoside phosphorylase Proteins 0.000 description 1
- 102100037825 Glycosaminoglycan xylosylkinase Human genes 0.000 description 1
- 101710117103 Glycosaminoglycan xylosylkinase Proteins 0.000 description 1
- 241000206595 Halomonas elongata Species 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241001223867 Shewanella oneidensis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/385—Pyrimidine nucleosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01063—Polyphosphate--glucose phosphotransferase (2.7.1.63)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention belongs to the field of synthetic biology, and provides a polyglucose kinase mutant and application thereof, wherein the amino acid sequence of the mutant is the amino acid sequence with mutation shown in SEQ ID NO. 2, and the mutated amino acid are L102V, N Q, E150T and H153E, G N. A mutant of polyglucose kinase having at least one mutation site or retaining the mutation site and having more than 90% amino acid sequence homology with the mutant, wherein an enzyme-catalyzed optimal substrate is changed from D-glucose to D-arabinose. The 5-phosphate-D-arabinose can be further used for preparing compounds such as arabinoside, cytarabine, ara-adenosine, 2-amino ara-adenosine, ara-guanosine and the like.
Description
Technical Field
The invention belongs to the field of synthetic biology, and particularly relates to a polyglucose kinase mutant and application thereof.
Background
Nucleosides are a class of polyhydroxy compounds that are precursors to natural nucleic acids, as well as structural components of many coenzymes. Therefore, the nucleoside and the derivative thereof have important application value in the fields of medicine, biochemistry and biotechnology. At present, nucleoside compounds play an important role in anti-AIDS, anti-tumor and other viral diseases treatment drugs applied clinically. Many nucleoside analogues are similar in structure to naturally occurring nucleosides and cannot be recognized by viruses in vivo, so that the nucleoside analogues can be effectively embedded in viral DNA chains, and can be competitively doped with nucleotides into the viral DNA chains to inhibit enzymes in the viral replication process, thereby inhibiting replication and reverse transcription of viral DNA, stopping or inhibiting extension and synthesis of viral DNA chains, and interfering expression of viral genes, so that the aim of treating diseases is fulfilled.
The preparation methods of nucleoside compounds and derivatives thereof can be divided into two types, namely chemical methods and enzymatic methods. Chemical methods are the traditional and mainstream methods of preparing such drugs at present. In recent years, the enzymatic preparation of nucleoside analogues has the advantages of high efficiency, high regioselectivity, mild reaction conditions, simplicity, controllability, environmental friendliness and the like, and overcomes the defects of low selectivity, more byproducts, more preparation and purification steps and the like of the common chemical method, so that the nucleoside analogues are increasingly valued. With the development of biotechnology, enzyme is used as a catalyst to link bases and ribose, which is a more common method in the field of preparation of nucleoside substances. When the nucleoside compound is synthesized by enzyme catalysis, the complex protection and deprotection steps are not needed for the base and ribose, so that the method has great economic and social benefits.
Arabinonucleosides are one type of nucleoside analogues, mainly consisting of arabinose linked to the base instead of ribose. Such compounds have been widely used in the pharmaceutical field, for example fludarabine, nelarabine, cytarabine, and the like. The synthesis of the compounds generally adopts relatively easily available arabinonucleoside (generally arabinoside, shown in formula b) as a raw material, and the corresponding products are obtained through two-step enzyme catalytic synthesis. As reported by Li Ping et al (Biotechnol bioeng.2022, 119, 1768-1780), expression of uridine phosphorylase and purine nucleoside phosphorylase in E.coli catalyzes the synthesis of cytarabine from arabinoside and cytosine (formula c). Also, as reported in the chinese patent application publication No. CN106929553a, the synthesis of arabinoside (formula d) from arabinoside and adenine by co-catalysis of uridine phosphorylase and purine nucleoside phosphorylase is reported. Furthermore, according to Liu Guosheng et al (J.Chi.A., 2016, volume 47, 857-860), it has been reported that arabino-guanosine (formula f) is produced from 2, 6-diaminopurine nucleoside (formula e) as a raw material by whole cell catalysis of Pseudomonas aeruginosa. However, the main starting material used in the above-described process is arabinonucleoside, which is hydrolysed to the base and 1-phospho-D-arabinose by a first enzyme, and subsequently the second enzyme catalyzes the synthesis of the corresponding nucleoside product from 1-phospho-D-arabinose and further base. The product is mainly obtained by base exchange through two steps of reactions, the price of raw materials is relatively high, and the product yield is relatively low.
Another method for obtaining 1-phosphate-D-arabinose is to catalyze the 5-hydroxyl phosphorylation of D-arabinose by ribose kinase or xylose kinase, but the phosphate donor of the enzyme is ATP, and the price is still relatively high. Although ATP can be regenerated in other ways, many regeneration methods face thermodynamic equilibrium problems and raw material costs (J. Jarooensuk et al, molecular Catalysis,2023,537,112937).
Disclosure of Invention
Aiming at the technical problems in the prior art, the invention provides a polyphosphate glucokinase mutant and application thereof, wherein the polyphosphate glucokinase mutant has high catalytic activity and good thermal stability on D-arabinose, and the enzyme is matched with different nucleoside phosphorylases to prepare the arabinoside, the 2-amino arabinoside and the arabinoside.
The technical scheme adopted by the invention is as follows: a mutant of the polyphosphoric glucokinase has an amino acid sequence shown in SEQ ID NO 2.
The invention modifies enzyme protein by combining rational design, directed evolution and high-throughput screening technology of enzyme. During the engineering process, the inventors found that the polyglucose kinase from Chloracidobacterium thermophilum was found in L102V, N Q, E150T, H153E, G205N. After mutation, the catalytic activity of the enzyme on arabinose is obviously improved. The amino acid sequence of the polyglucose kinase mutant is SEQ ID NO:2, and a polypeptide having the amino acid sequence shown in 2. The amino acid sequence of the mutant phosphoglucose kinase has mutation sites in the mutated amino acid sequence and has more than 90% of homology with the mutated amino acid sequence.
A gene of a mutant of the polyphosphate glucokinase, which is derived from Chloracidobacterium thermophilum wild type polyphosphate glucokinase SEQ ID NO 1. The substrate for the enzyme obtained after expression of these genes is glucose, while the catalytic activity for D-arabinose is low. The invention provides a polyphosphoric acid glucokinase mutant which has higher activity to a substrate shown in a formula a.
The technical scheme adopted by the invention is as follows: a recombinant carrier containing the gene of the polyphosphoric acid glucokinase mutant is constructed by connecting the nucleotide sequence of the polyphosphoric acid glucokinase gene to various prokaryotic expression carriers or eukaryotic expression carriers, such as pGEX, pMAL, pET series prokaryotic expression carriers and eukaryotic expression carriers. Preferably, pET series plasmids are used as starting vectors, in particular pET-24a.
The technical scheme adopted by the invention is as follows: a genetically engineered bacterium for producing the mutant of the polyglucose kinase comprises the recombinant vector, and the host cell is escherichia coli (Escherichia coli BL (DE 3)).
The technical scheme adopted by the invention is as follows: a method for preparing a mutant of polyglucose kinase, comprising the following steps: culturing the genetically engineered bacteria to obtain recombinant polyglucose kinase mutant.
Further, the method comprises the steps of fermenting and culturing the genetically engineered bacteria, and collecting and preparing recombinant polyglucose kinase mutants. Specifically, the step of industrially preparing the recombinant polyglucose kinase and mutants thereof is carried out in a fermentation tank according to certain fermentation conditions; the fermentation conditions of the production tank are preferably as follows: DO is above 20%, and the air flow is 1:0.5-2 vvm.
The technical scheme adopted by the invention is as follows: the application of the polyphosphate glucokinase mutant is applied to a phosphate transfer reaction, takes the polyphosphate as a phosphate donor, phosphorylates D-arabinose shown in a formula a, and is further used for preparing beta-D-arabinonucleoside shown in a formula b, a formula c, a formula D, a formula e and a formula f;
formula a is D-arabinose, formula b is arabinoside, formula c is cytarabine, formula D is arabinoside, formula e is 2-amino arabinoside, and formula f is arabinogaoside.
The invention uses low-price and easily available D-arabinose and polyphosphoric acid as raw materials to produce 5-phosphoric acid-D-arabinose, and then uses glucose phosphate isomerase to catalyze and synthesize 1-phosphoric acid-D-arabinose. Most of the studies have been carried out with the phosphate donor ATP being very expensive in the preparation of 5-phosphate-arabinose. The polyphosphate dependent glucokinase mutant adopted by the invention takes the polyphosphate as a phosphate donor, but most of the enzymes take glucose as a substrate, the catalytic activity is low when catalyzing the phosphorylation of the arabinose, and the invention combines the rational design, directed evolution and high-flux screening technology of the enzyme to modify the enzyme protein, so as to obtain the polyphosphate glucokinase mutant with high D-arabinose catalytic activity and good thermal stability. The invention combines the mutant of the polyphosphoric glucokinase and isomerase, pyrimidine nucleoside phosphorylase or purine nucleoside phosphorylase to synthesize the arabinoside, the cytarabine, the arabinoside, the 2-amino arabinoside and the arabino-guanosine.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention provides a mutant of polyphosphate glucokinase, which can improve the activity of enzyme on a compound shown in a formula a, and can be used for the synthesis reaction of arabinoside with structures shown in a formula b, a formula c, a formula d, a formula e and a formula f.
2. The enzyme has excellent catalytic activity on D-arabinose; when the mutant is used for preparing the compounds shown in the formulas b, c, D, e and f, the adopted raw materials are D-arabinose and polyphosphoric acid which are easier to obtain and have low cost; when the arabinonucleoside is prepared, the catalyzed reaction is simple and mild, no waste is discharged, the reaction conversion rate is high, and the method has a good application prospect.
Detailed Description
In order to enable those skilled in the art to better understand the technical scheme of the present invention, the present invention will be described in detail with reference to specific embodiments.
The embodiment of the invention provides a polyglucose kinase mutant and application thereof, which specifically comprises the following steps:
1: acquisition of thermostable polyglucose kinase
The wild type polyglucose kinase shown in SEQ ID No.1 is subjected to DNA codon optimization, then a gene synthesis company artificially synthesizes a complete gene fragment, the gene is inserted into NdeI and BamHI sites of pET-24a plasmid, and the connected vector is transferred into escherichia coli BL21 (DE 3) to establish the polyglucose kinase genetic engineering strain.
2: mutant of polyphosphoric acid glucokinase
The three-dimensional structure of the polyphosphate glucokinase (SEQ ID NO 1) derived from Chloracidobacterium thermophilum has not been revealed yet. However, the invention uses SWISS-MODEL to construct a three-dimensional MODEL of the wild-type gene sequence, and discovers that the homology of the wild-type gene sequence with uracil nucleoside phosphorylase (PDB ID:1 woq) from Arthrobacter sp.strain KM is 44.44%, and the enzyme functions are similar. Thus, by referring to the three-dimensional structure of the enzyme, the binding simulation of the substrate of formula a to the protein was performed by molecular docking software, and finally by Pymol analysis, the amino acids that are likely to be associated with D-arabinose binding were selected to be 65P, 66S, 78N, 104N, 105D, 106A, 135I, 136G, 150E, 153H, 162E, the sites that bind to ATP, ADP or polyphosphoric acid included 6G, 7G, 8T, 9G, 11K, 28R, 132G, 133T, 167L, 205G, 230N, and the amino acids of these sites were taken as rationally designed mutation sites for saturation mutation.
In addition to the rational design, the invention utilizes an error-prone PCR random mutation method to carry out protein engineering modification on the polyglucose kinase. In general, error-prone PCR can be used to randomly introduce mutations into a target gene at a certain frequency by adjusting reaction conditions (e.g., increasing magnesium ion concentration, adding manganese ions, changing dNTP concentrations of four species in a system, or using low-fidelity DNA polymerase) to change the mutation frequency during amplification when the target gene is amplified by DNA polymerase, thereby obtaining random mutants of protein molecules.
The invention adopts Taq polymerase with lower fidelity and simultaneously utilizes Mn 2+ Substitution of the natural cofactor Mg 2+ Increasing the probability of error.
The 50. Mu.L PCR system was as follows:
wherein: the polyglucose kinase template gene is recombinant plasmid constructed by inserting a gene with SEQ ID NO.1 and optimized codons into pET-24a plasmid; the invention designs the primer according to the upstream and downstream sequences of the target gene in the recombinant plasmid.
The PCR reaction conditions were: pre-denaturation at 95℃for 2.5min; denaturation at 94℃for 15s, annealing at 53℃for 30s, extension at 72℃for 60s for 35 cycles; the extension was continued at 72℃for 10min and cooled to 4 ℃.
The PCR amplified product was ligated to pET-24a vector and transferred into E.coli BL21 (DE 3) to create a polyglucose kinase gene mutation library.
The Escherichia coli BL21 (DE 3) is used as a host, and the pET-24a plasmid is used as a vector to express the polyphosphate glucokinase. The amino acid sequence of the screened high-activity polyglucose kinase mutant gene is shown as SEQ ID NO 2.
3: small-scale production of polyglucokinase and its mutant, purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase in shake flask
Coli containing the recombinant plasmid was inoculated into 50mL of LB medium (peptone 10g/L, yeast extract 5g/L, naCl 10g/L, pH 7.2) containing kanamycin (50. Mu.g/mL). Shake-culturing at 37℃and 210rpm for 16 hours. Then transferring into 100mL LB medium containing kanamycin according to the ratio of 1:100, shake culturing at 37deg.C and 210rpm, and measuring absorbance (OD) of bacterial liquid at 600nm at regular time 600 ) To monitor the cell growth density. When the OD of the culture 600 When the enzyme is in the range of 0.6 to 0.8, isopropyl beta-D-thiogalactoside (IPTG) with the final concentration of 0.2mM is added to induce the expression of the target enzyme gene, and the target enzyme gene is induced and cultured overnight (more than or equal to 16 hours). Centrifugation at 10000rpm at 4℃for 10min, discarding the supernatant, and after re-suspending the cell pellet at 200g/L with pre-chilled 100mM phosphate buffer (pH 7.0), ultrasonication, centrifugation at 13000rpm at 4℃for 30min, collecting the supernatant, i.e., crude enzyme solution, and storing at-20 ℃.
4: preparation of cytarabine
The preparation system of cytarabine is as follows:
4mM magnesium sulfate, 200mM D-glucose, 100mM polyphosphate, 50mM HEPES buffer, 30mM cytosine, 100ml/L of wild-type polyglucose kinase or mutant crude enzyme solution thereof, 100ml/L of Thermococcus kodakarensis phosphoglucose isomerase (SEQ ID NO. 3), 100ml/L of Geobacillus stearothermophilus pyrimidine nucleoside phosphorylase (SEQ ID NO. 4) crude enzyme solution, and pH=7.5 of the system was adjusted with sodium hydroxide. The reaction was carried out at 55℃for 3h. When wild-type polyglucose kinase was used as the catalytic enzyme, the yield was 9% in terms of cytosine. When the mutant of polyglucose kinase is used as the catalytic enzyme, the yield is 69% calculated by cytosine.
5: preparation of Alzhugan
4mM magnesium sulfate, 200mM D-glucose, 100mM polyphosphate, 50mM HEPES buffer, uracil 30mM, wild-type polyglucose kinase or its mutant crude enzyme solution 100ml/L, thermococcus kodakarensis phosphoglucose isomerase (SEQ ID NO. 3) 100ml/L, shewanella oneidensis uridine phosphorylase (SEQ ID NO. 5) crude enzyme solution 100ml/L, and the system was adjusted to pH=7.5 with sodium hydroxide. The reaction was carried out at 55℃for 3h. When wild-type polyglucose kinase was used as the catalytic enzyme, the yield was 12% in terms of uracil. When the mutant of polyglucose kinase is used as the catalytic enzyme, the yield is 76% based on uracil.
6: preparation of arabinoside
4mM magnesium sulfate, 200mM D-glucose, 100mM polyphosphate, 50mM HEPES buffer, adenine 30mM, crude enzyme solution of wild type polyglucokinase or mutant thereof 100ml/L, crude enzyme solution of Thermococcus kodakarensis phosphoglucose isomerase (SEQ ID NO. 3) 100ml/L, aeropyrumpernix purine nucleoside phosphorylase (SEQ ID NO. 6) 100ml/L, and pH of the system adjusted with sodium hydroxide=7.5. The reaction was carried out at 55℃for 3h. When wild-type polyglucose kinase was used as the catalytic enzyme, the yield was 13% in terms of adenine. When the mutant of polyglucose kinase is used as the catalytic enzyme, the yield is 89% in terms of adenine.
7: preparation of 2-amino arabinoside
4mM magnesium sulfate, 200mM D-glucose, 100mM polyphosphate, 50mM HEPES buffer, 30mM 2-aminoadenine, 100ml/L of wild-type polyglucose kinase or mutant crude enzyme solution, 100ml/L, thermoclostridiumcaenicola purine nucleoside phosphorylase (SEQ ID NO. 3) 100ml/L of Thermococcus kodakarensis phosphoglucose isomerase (SEQ ID NO. 7) crude enzyme solution, and the system was adjusted to pH=7.5 with sodium hydroxide. The reaction was carried out at 55℃for 3h. When wild-type polyglucose kinase was used as the catalytic enzyme, the yield was 11% based on 2-aminoadenine. When the mutant of polyglucose kinase is used as the catalytic enzyme, the yield is 86% based on 2-amino adenine.
8: preparation of arabinogalactan
4mM magnesium sulfate, 200mM D-glucose, 100mM polyphosphate, 50mM HEPES buffer, guanine 30mM, crude enzyme solution of wild-type polyglucose kinase or mutant thereof 100ml/L, crude enzyme solution of Thermococcus kodakarensis phosphoglucose isomerase (SEQ ID NO. 3) 100ml/L, halomonas elongata purine nucleoside phosphorylase (SEQ ID NO. 8) 100ml/L, and the system was adjusted in valence pH=7.5 with sodium hydroxide. The reaction was carried out at 55℃for 3h. When wild-type polyglucose kinase was used as the catalytic enzyme, the yield was 11% based on 2-aminoadenine. When the mutant of polyglucose kinase is used as the catalytic enzyme, the yield is 86% based on 2-amino adenine.
8: HPLC detection (yield) of nucleosides
The measurement is carried out by high performance liquid chromatography (China pharmacopoeia 2020 edition, four-part rule 0512).
Solvent: water-methanol (85:15).
Chromatographic conditions: octadecylsilane chemically bonded silica (4.6X105 mm,5 μm or column with equivalent performance) is used as filler; water (0.1% phosphoric acid) is used as a mobile phase A, acetonitrile is used as a mobile phase B, and linear gradient elution is carried out; the flow rate is 1.0ml per minute; the column temperature is 35 ℃; the detection wavelength is 254nm; the sample volume was 5. Mu.l.
Table 1 table of variation of mobile phase ratio in HPLC detection method
Time (minutes) | Mobile phase a (%) | Mobile phase B (%) |
0 | 90 | 10 |
3 | 90 | 10 |
15 | 60 | 40 |
18 | 10 | 90 |
18.1 | 90 | 10 |
22 | 90 | 10 |
Assay: precisely measuring the solution of the sample, injecting into a liquid chromatograph, and recording the chromatogram.
The present invention has been described in detail by way of examples, but the description is merely exemplary of the invention and should not be construed as limiting the scope of the invention. The scope of the invention is defined by the claims. In the technical scheme of the invention, or under the inspired by the technical scheme of the invention, similar technical schemes are designed to achieve the technical effects, or equivalent changes and improvements to the application scope are still included in the protection scope of the patent coverage of the invention.
Claims (6)
1. A mutant polyphosphate glucokinase, characterized in that: the amino acid sequence is shown as SEQ ID NO 2.
2. A recombinant vector comprising the gene of the mutant polyglucose kinase of claim 1, characterized in that: pET series plasmid is taken as an initial vector.
3. A genetically engineered bacterium for producing the polyglucose kinase mutant of claim 1, characterized in that: the genetically engineered bacterium comprises the recombinant vector of claim 2, and the host cell is escherichia coli.
4. A method for preparing a mutant of polyglucose kinase, which is characterized by comprising the following steps: culturing the genetically engineered bacterium of claim 3 to obtain a recombinant polyglucose kinase mutant.
5. The method for producing a mutant of polyglucose kinase as defined in claim 4, wherein: fermenting and culturing the genetically engineered bacteria.
6. Use of the mutant phosphoglucose kinase as claimed in claim 1, characterized in that: the method is applied to a phosphate transfer reaction, takes polyphosphoric acid as a phosphate donor, phosphorylates D-arabinose shown in a formula a, and is further used for preparing beta-D-arabinose nucleosides shown in a formula b, a formula c, a formula D, a formula e and a formula f;
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311176882.2A CN117402851A (en) | 2023-09-13 | 2023-09-13 | Polyglucose kinase mutant and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311176882.2A CN117402851A (en) | 2023-09-13 | 2023-09-13 | Polyglucose kinase mutant and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117402851A true CN117402851A (en) | 2024-01-16 |
Family
ID=89495218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311176882.2A Pending CN117402851A (en) | 2023-09-13 | 2023-09-13 | Polyglucose kinase mutant and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117402851A (en) |
-
2023
- 2023-09-13 CN CN202311176882.2A patent/CN117402851A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8759034B2 (en) | Thermostable biocatalyst combination for nucleoside synthesis | |
Tabata et al. | Production of N-acetyl-D-neuraminic acid by coupling bacteria expressing N-acetyl-D-glucosamine 2-epimerase and N-acetyl-D-neuraminic acid synthetase | |
JP4505011B2 (en) | Enzymatic synthesis of 3'-phosphoadenosine-5'-phosphosulfate | |
CN113755414B (en) | Recombinant microorganism for producing uridine and method for producing uridine | |
EP1816206B1 (en) | Method of producing uridine 5 -diphospho-n-acetylgalactosamine | |
CN114350727B (en) | Method for synthesizing D-psicose by combining phosphorylation and ATP regeneration system | |
Qian et al. | Phosphorylation of uridine and cytidine by uridine–cytidine kinase | |
CN113755413A (en) | Recombinant microorganism producing beta-nicotinamide mononucleotide and method for producing NMN (N-methyl-N) by using same | |
CN113755411B (en) | Recombinant microorganism for high-yield of beta-nicotinamide mononucleotide and method for producing beta-nicotinamide mononucleotide by recombinant microorganism | |
KR100922085B1 (en) | Processes for producing cmp-n-acetylneuraminic acid | |
CN114480461B (en) | Recombinant microorganism for producing beta-nicotinamide mononucleotide and construction method and application thereof | |
CN113755416A (en) | Recombinant microorganism with novel synthetic pathway for producing beta-thymidine and method for producing beta-thymidine | |
TW201732039A (en) | New polyphosphate-dependent glucokinase and method for preparing glucose 6-phosphate using the same | |
CN106834176B (en) | Nucleoside phosphorylase, coding gene, high-yield strain thereof and application | |
CN117402851A (en) | Polyglucose kinase mutant and application thereof | |
JP3833584B2 (en) | Process for producing CMP-N-acetylneuraminic acid | |
CN118048349A (en) | Deaminase mutant and application thereof | |
CN117106837A (en) | Method for synthesizing 2-amino-arabinoside by enzyme method | |
CN117070582A (en) | Method for synthesizing beta-nicotinamide mononucleotide by hypoxanthine-guanine phosphoribosyl transferase | |
CN117925754A (en) | Method for synthesizing beta-nicotinamide mononucleotide by uracil phosphoribosyl transferase | |
CN116904430A (en) | Protein mutant capable of improving nucleoside yield of strain and application thereof | |
CN117143942A (en) | Synthesis method of 3 '-amino-2', 3 '-dideoxyguanosine 5' -triphosphate | |
CN116555378A (en) | Method for producing ribonucleosides or derivatives thereof, biological enzyme preparations and use thereof | |
CN117757876A (en) | Double-enzyme catalysis preparation method of 2' -deoxy-2-fluoroadenosine | |
CN113151238A (en) | Pentose phosphate mutase mutant and application thereof in constructing bacillus subtilis with high nucleoside yield |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |